Skip to main content

Table 4 Reasons for discontinuation of immunosuppressive/antiproliferative and vasoactive agents in 181 patients with systemic sclerosis

From: Treatment modalities and drug survival in a systemic sclerosis real-life patient cohort

 InefficacyAdverse eventDisease stabilizationMiscellaneous
Methotrexate (n = 49/106)*20 (41%)15 (30%)10 (21%)4 (8%)
Cyclophospamide (n = 35/48)11 (31%)9 (26%)10 (29%)5 (14%)
Mycophenolate (n = 18/27)6 (33%)5 (27%)4 (22%)3 (22%)
Azathioprine (n = 13/16)7 (54%)3 (23%)3 (23%)
Rituximab (n = 3/6)1 (33%)1 (33%)1 (33%)
Tocilizumab (n = 3/13)1 (33%)1 (33%)1 (33%)
ERAs (n = 17/83)2 (12%)12 (71%)3 (17%)
 Bosentan (n = 14/71)1 (7%)10 (71%)3 (21%)
 Abrisentan (n = 2/7)1 (50%)1 (50%)
 Macitentan (n = 1/5)1 (100%)
Iloprost (n = 8/12)1 (13%)4 (50%)3 (37%)
Sildenafil (n = 3/15)1 (33%)2 (66%)
  1. *n of agents discontinued/n of agents administered